- Malaria is a life-threatening public health issue, particularly
in low- and middle-income countries. There is a need for an
effective, affordable, and accessible preventive and/or treatment
medication. This potential partnership is a step towards this
cause
- This potential partnership aims to bring together Kainomyx’s
expertise in novel drug discovery, Aurigene’s capability to conduct
integrated drug discovery and development, and Dr. Reddy’s ability
to commercialize products in low and middle-income countries, in
addition to the US and Europe
- It is a testament to the commitment of involved parties towards
promoting global public health and Dr. Reddy’s goal of reaching 1.5
billion patients by 2030
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY, NSEIFSC: DRREDDY; along with its subsidiaries together
referred to as “Dr. Reddy’s”), and its CRDMO arm Aurigene
Pharmaceutical Services Limited (Aurigene), today announced that
they have signed a non-binding Memorandum of Understanding (MoU)
with Kainomyx, Inc., a US-based company with a proprietary platform
that helps target cytoskeletal proteins of parasites, a novel
mechanism of action, for the development and commercialization of
affordable anti-malarial drug in the U.S., Europe, and in low and
middle-income countries. The MoU remains subject to signing of a
definitive agreement.
Malaria is a serious health challenge that has a
disproportionate prevalence in vulnerable populations of low-income
countries. As per WHO, an alarming number of 249 million malaria
cases and 608,000 cases of malaria death were reported in year
2022. It has been widely reported that climate change will increase
the incidences of such vector-borne diseases1. With this
collaboration, the companies intend to drive a comprehensive
research and development agenda to leverage their strengths and
accelerate the program.
Under the MoU, Kainomyx has agreed to lead the technical
strategy and associated aspects for drug discovery and clinical
phases, Aurigene has agreed to focus on developing cost-effective
and scalable drug chemistry, and while the program evolves, Dr.
Reddy’s will bring in its regulatory and market access
expertise.
Deepak Sapra, CEO – API and Services, Dr. Reddy’s
Laboratories Ltd., said: “Public health and access is a
strategic area for us and malaria continues to be a very important
disease that needs innovative as well as affordable medicines. The
MoU with Kainomyx is a promising step in that direction and towards
improving global health outcomes and delivering on Dr. Reddy’s
vision to reach 1.5 billion patients by 2030.”
Akhil Ravi, CEO, Aurigene Pharmaceutical Services Ltd.,
adds, “We are excited to collaborate with Dr. James and the
Kainomyx team given their expertise in bringing innovative
medicines to market. We share the same vision of addressing global
health issues by serving neglected populations.”
James Spudich, Executive Chairman of Kainomyx, states,
“new drug discovery for Malaria and other parasitic diseases is
essential because drug resistance to existing therapeutics is
rapidly developing. Through our decades of work, we have developed
a deep understanding of how cytoskeletal proteins work.
Cytoskeletal proteins are essential for all living organisms, and
we are exploiting this to specifically target the cytoskeleton for
treatment of Malaria. I am delighted that in our molecules’ journey
to market we will be forming a partnership with Dr. Reddy’s and
Aurigene who have demonstrated their experience and expertise
through their work in public health.”
About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global
pharmaceutical company headquartered in Hyderabad, India.
Established in 1984, we are committed to providing access to
affordable and innovative medicines. Driven by our purpose of 'Good
Health Can't Wait', we offer a portfolio of products and services
including APIs, generics, branded generics, biosimilars and OTC.
Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and
dermatology. Our major markets include – USA, India, Russia &
CIS countries, China, Brazil and Europe. As a company with a
history of deep science that has led to several industry firsts, we
continue to plan ahead and invest in businesses of the future. As
an early adopter of sustainability and ESG actions, we released our
first Sustainability Report in 2004. Our current ESG goals aim to
set the bar high in environmental stewardship; access and
affordability for patients; diversity; and governance. For more
information, log on to: www.drreddys.com.
About Aurigene: Aurigene, a Dr. Reddy’s Laboratories
company, is a global contract research, development, and
manufacturing organization (CRDMO) built on the legacy of
accelerating innovation and backed by a vast experience in drug
discovery, development, and manufacturing of small and large
molecules. We offer integrated and standalone services for
discovery chemistry, biotherapeutics discovery, discovery biology,
development and manufacturing services for clinical phase I-III
programs, regulatory submission batches and commercial
manufacturing. For more details about Aurigene, please visit
www.aurigeneservices.com.
LinkedIn YouTube
About Kainomyx: Kainomyx Inc. is a California-based,
Stanford spinout leveraging its expertise in targeting cytoskeletal
proteins for human, animal and agricultural diseases. The company
was founded in 2019 by James Spudich, Ph.D., Annamma Spudich Ph.D.,
Darshan Trivedi Ph.D., Suman Nag Ph.D., and Kathleen Ruppel
MD-Ph.D., who have decades of experience in cytoskeletal biology.
This team was involved in the discovery of the first-in-class
cardiac myosin inhibitor CamzyosTM developed by MyoKardia (FDA
approved in April 2022) for the treatment of hypertrophic
cardiomyopathy. James Spudich was a Founder of MyoKardia (acquired
by Bristol Myers Squibb) and Cytokinetics, both of which leverage
cytoskeletal targeting for human muscle diseases. He and his
co-Founders of Kainomyx Inc. have developed programs focused on
targeting cytoskeletal proteins for global health diseases,
including Malaria and other programs in animal and agricultural
spaces. Kainomyx Inc. has also established a subsidiary in C-CAMP,
Bangalore, India to pursue their research programs. For more
details about Kainomyx, please visit www.kainomyx.com
LinkedIn
1 https://www.who.int/news-room/fact-sheets/detail/malaria
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on
the management's current views and assumptions and involve known or
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. In addition to statements which are
forward-looking by reason of context, the words "may", "will",
"should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar
expressions identify forward-looking statements. Actual results,
performance or events may differ materially from those in such
statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults , currency exchange rates, interest rates, persistency
levels and frequency / severity of insured loss events, (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization,
including related integration issues, and (vi) the susceptibility
of our industry and the markets addressed by our, and our
customers', products and services to economic downturns as a result
of natural disasters, epidemics, pandemics or other widespread
illness, including coronavirus (or COVID-19), and (vii) other risks
and uncertainties identified in our public filings with the
Securities and Exchange Commission, including those listed under
the "Risk Factors" and "Forward-Looking Statements" sections of our
Annual Report on Form 20-F for the year ended March 31, 2024. The
company assumes no obligation to update any information contained
herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240820774139/en/
Media Contact: USHA IYER; ushaiyer@drreddys.com
Dr Reddys Laboratories (NYSE:RDY)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Dr Reddys Laboratories (NYSE:RDY)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024